By early 2026, Chinese biotech innovation has moved from a “fast-follower” role to a primary global engine for first-in-class oncology assets. Chinese firms now drive 70% of the global ADC pipeline and 60% of bispecific antibody development. Proprietary platforms are now addressing the high toxicity and limited efficacy seen in previous generations of Western therapeutics.
Breakthrough Assets in Chinese Biotech Innovation
Leading the 2026 innovation cycle are assets that have outperformed established standard-of-care blockbusters in head-to-head trials.
- Ivonescimab (AK112): Akeso’s PD-1/VEGF bispecific demonstrated a historic 49% reduction in disease progression compared to Keytruda in first-line NSCLC, as confirmed in the HARMONi-2 primary analysis.
- Sac-TMT (SKB264): Sichuan Kelun-Biotech’s TROP2 ADC received NMPA approval and Breakthrough Therapy Designation in 2025, showing superior PFS in breast cancer trials. Details are available via Kelun-Biotech’s Newsroom.
- Autoimmune Bispecifics: Qyuns Therapeutics (2025 Interim Report) has advanced QX005N into Phase III, marking a shift toward long-acting immunology solutions.
Strategic Modality Comparison
| Modality | Global Pipeline Share | Key Developer | 2026 Status |
|---|---|---|---|
| ADCs | 70% | Kelun-Biotech | NMPA Approved / FDA Phase III |
| Bispecifics | 60% | Akeso / Summit | NRDL Included (Jan 2026) |
| siRNA | Emerging | Suzhou Ribo | Listed HKEX (Jan 2026) |
References
- Akeso/Summit: HARMONi-A Overall Survival Data (Nov 2025)
- Kelun-Biotech: sac-TMT Approval & Breakthrough Status (2025)
- Qyuns Therapeutics: 2025 Interim Results & Clinical Milestones